Management of relapse after CAR-T

Management of R/R myeloma including CAR-T and BispecificsПодробнее

Reasons for Failure and Relapse and Mechanisms of Resistance in CAR-TПодробнее

What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?Подробнее

Strategies to prevent relapse and changing paradigm in the management of relapsed DLBCLПодробнее

Transplant or CAR T-cell Therapy for Lymphoma? How to Make the ChoiceПодробнее

Episode 078: Management of relapsed diffuse large B-cell lymphoma (DLBCL) - Part 2Подробнее

Managing the practicalities of CAR T-cell therapies in patients with R/R MCLПодробнее

Improving survival outcomes and optimizing CAR-T therapy in patients with DLBCLПодробнее

What is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?Подробнее

Marc Schwartz, MD - Management of Adults with Relapsed/Refractory ALL - CU SymposiaПодробнее

Early and Late complications after CAR T therapyПодробнее

Managing early & late relapse after first-line therapy for DLBCLПодробнее

Phase I study of CD22 CAR-T therapy in patients with LBCL who have relapsed after CD19 CAR-T therapyПодробнее

Exploring available third-line treatment options for R/R DLBCL: CAR-T, bispecifics, ADCs & mAbsПодробнее

Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma | LRF WebinarsПодробнее

New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed DiseaseПодробнее

Anti-BCMA Bispecific Antibody for Myeloma Relapse After CAR T CellsПодробнее

CAR T-cell Therapy: Acute Lymphoblastic Leukemia - A Drive through the Past, Present and FutureПодробнее

Evaluating the role of autoSCT in patients with DLBCL who relapse after first-line therapyПодробнее

Update on CAR T-Cell Therapy | LRF WebinarsПодробнее